Association Between the (GT)26 Allele in the GRIN2A Promoter and Opioid Use Disorder.

IF 1.8 4区医学 Q3 PSYCHIATRY

Psychiatry Investigation Pub Date : 2025-06-01 Epub Date: 2025-06-16 DOI:10.30773/pi.2025.0090

Xiaohu Xie, Dingding Zhuang, Longhui Li, Tingting Wu, Wenwen Shen, Yue Liu, Wenjin Xu, Qingxiao Hong, Zemin Xu, Weisheng Chen, Jun Gu, Wenhua Zhou, Huifen Liu

{"title":"Association Between the (GT)26 Allele in the GRIN2A Promoter and Opioid Use Disorder.","authors":"Xiaohu Xie, Dingding Zhuang, Longhui Li, Tingting Wu, Wenwen Shen, Yue Liu, Wenjin Xu, Qingxiao Hong, Zemin Xu, Weisheng Chen, Jun Gu, Wenhua Zhou, Huifen Liu","doi":"10.30773/pi.2025.0090","DOIUrl":null,"url":null,"abstract":"Objective: N-methyl-D-aspartate (NMDA) receptors are involved in the development of opioid use disorder. The (GT)n polymorphism (rs3219790) in the NMDA receptor 2A subunit gene (GRIN2A) has been proposed as a potential biomarker for risk of opioid use disorder. In this case-control study, we investigated the association between rs3219790 and opioid use disorder in a Chinese Han population.Methods: A total of 538 heroin dependent patients and 400 healthy controls were recruited. The genotypes of (GT)n repeats were determined using a polymerase chain reaction-amplifying fragment length polymorphism assay. The association of the (GT)n polymorphism with opioid use disorder and cravings was assessed.Results: The frequency of the (GT)26 allele in patients with opioid use disorder was significantly greater than that in the controls (p=0.029, odds ratio=1.264, 95% confidence interval=1.025-1.560), consistent with previous findings. Compared with homozygous carriers of short alleles, carriers of long alleles demonstrated significantly stronger drug cravings (p<0.05).Conclusion: The results confirm that the (GT)26 allele of rs3219790 in the GRIN2A promoter is associated with opioid use disorder. Additionally, a longer rs3219790 allele is correlated with stronger drug cravings.","PeriodicalId":21164,"journal":{"name":"Psychiatry Investigation","volume":"22 6","pages":"730-735"},"PeriodicalIF":1.8000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Psychiatry Investigation","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.30773/pi.2025.0090","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/6/16 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"PSYCHIATRY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: N-methyl-D-aspartate (NMDA) receptors are involved in the development of opioid use disorder. The (GT)n polymorphism (rs3219790) in the NMDA receptor 2A subunit gene (GRIN2A) has been proposed as a potential biomarker for risk of opioid use disorder. In this case-control study, we investigated the association between rs3219790 and opioid use disorder in a Chinese Han population.

Methods: A total of 538 heroin dependent patients and 400 healthy controls were recruited. The genotypes of (GT)n repeats were determined using a polymerase chain reaction-amplifying fragment length polymorphism assay. The association of the (GT)n polymorphism with opioid use disorder and cravings was assessed.

Results: The frequency of the (GT)26 allele in patients with opioid use disorder was significantly greater than that in the controls (p=0.029, odds ratio=1.264, 95% confidence interval=1.025-1.560), consistent with previous findings. Compared with homozygous carriers of short alleles, carriers of long alleles demonstrated significantly stronger drug cravings (p<0.05).

Conclusion: The results confirm that the (GT)26 allele of rs3219790 in the GRIN2A promoter is associated with opioid use disorder. Additionally, a longer rs3219790 allele is correlated with stronger drug cravings.

查看原文本刊更多论文

GRIN2A启动子（GT）26等位基因与阿片类药物使用障碍的关系

目的：n -甲基- d -天冬氨酸受体参与阿片类药物使用障碍的发生发展。NMDA受体2A亚基基因（GRIN2A）的（GT）n多态性（rs3219790）被认为是阿片类药物使用障碍风险的潜在生物标志物。在本病例对照研究中，我们调查了rs3219790与中国汉族人群阿片类药物使用障碍之间的关系。方法：招募海洛因依赖患者538例，健康对照400例。采用聚合酶链反应扩增片段长度多态性测定（GT）n重复序列的基因型。评估（GT）n多态性与阿片类药物使用障碍和渴望的关系。结果：阿片类药物使用障碍患者中（GT）26等位基因的频率显著高于对照组（p=0.029，优势比=1.264,95%可信区间=1.025-1.560），与既往研究结果一致。与纯合子短等位基因携带者相比，长等位基因携带者表现出更强的药物渴望(p结论：结果证实GRIN2A启动子rs3219790的（GT）26等位基因与阿片类药物使用障碍有关。此外，较长的rs3219790等位基因与更强烈的药物渴望相关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Psychiatry Investigation PSYCHIATRY-

CiteScore

4.10

自引率

3.70%

发文量

105

审稿时长

6-12 weeks

期刊介绍： The Psychiatry Investigation is published on the 25th day of every month in English by the Korean Neuropsychiatric Association (KNPA). The Journal covers the whole range of psychiatry and neuroscience. Both basic and clinical contributions are encouraged from all disciplines and research areas relevant to the pathophysiology and management of neuropsychiatric disorders and symptoms, as well as researches related to cross cultural psychiatry and ethnic issues in psychiatry. The Journal publishes editorials, review articles, original articles, brief reports, viewpoints and correspondences. All research articles are peer reviewed. Contributions are accepted for publication on the condition that their substance has not been published or submitted for publication elsewhere. Authors submitting papers to the Journal (serially or otherwise) with a common theme or using data derived from the same sample (or a subset thereof) must send details of all relevant previous publications and simultaneous submissions. The Journal is not responsible for statements made by contributors. Material in the Journal does not necessarily reflect the views of the Editor or of the KNPA. Manuscripts accepted for publication are copy-edited to improve readability and to ensure conformity with house style.